Index of artpub/2024/310398/

Girolomoni, Gampiero
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
2024
https://ddd.uab.cat/record/310398